In addition, NY-ESO-1-specific CD4+ T cells isolated from a metastatic melanoma patient after treatment with ipilimumab were able to directly lyse autologous cancer cells, suggesting an added clinical benefit of eliciting a NY-ESO-1 CD4+ cellular response (134). Here, CTAG1B is linked to cancer.